Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:MADHAVBAUG'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.21 Max: 3.06
Current: 0.15
During the past 8 years, the highest Debt-to-EBITDA Ratio of Vaidyane Ayurved Laboratories was 3.06. The lowest was 0.02. And the median was 0.21.
NSE:MADHAVBAUG's Debt-to-EBITDA is ranked better than 82.97% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs NSE:MADHAVBAUG: 0.15
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vaidyane Ayurved Laboratories Debt-to-EBITDA Related Terms
Vaidyane Ayurved Laboratories Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Debt-to-EBITDA of 0.16 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vaidyane Ayurved Laboratories. This is 24% below median its historical median of 0.21. Over the past decade, Vaidyane Ayurved Laboratories' Debt-to-EBITDA has ranged from 0.02 to 3.06. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #116 out of 681 companies in the Drug Manufacturers industry, placing it in the top 17%.
Is Vaidyane Ayurved Laboratories' Debt-to-EBITDA too high?
Vaidyane Ayurved Laboratories' current Debt-to-EBITDA of 0.16 is 24% below median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 3.06. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Vaidyane Ayurved Laboratories' value of 0.16 is 90.2% below this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #116 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #116 out of 681 companies for Debt-to-EBITDA. This places Vaidyane Ayurved Laboratories in the top 17% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.63. Vaidyane Ayurved Laboratories' value of 0.16 is 90.2% below this benchmark. Historically, Vaidyane Ayurved Laboratories' own Debt-to-EBITDA has ranged from 0.02 to 3.06 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 1.63, Vaidyane Ayurved Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Debt-to-EBITDA of 0.16 is 90.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vaidyane Ayurved Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Debt-to-EBITDA is 0.16, which is 24% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.27, compared to a current price of ₹169.45 — trading 25.8% below its estimated fair value. The current Debt-to-EBITDA is 0.16, which is 24% below median its 10-year median of 0.21 and 90.2% below the Drug Manufacturers industry median of 1.63. Vaidyane Ayurved Laboratories' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Debt-to-EBITDA is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹169.45 is trading 25.8% below its estimated GF Value™ of ₹228.27.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
Debt-to-EBITDA: 0.16 (24% below median its 10-year median of 0.21)
GF Value™: ₹228.27 vs. price of ₹169.45 (25.8% below fair value)
Industry Position: 90.2% below the Drug Manufacturers median (#116 of 681)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
77GF Score
Get the complete analysis for NSE:MADHAVBAUG
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
